• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by ETHZilla Corporation

    11/5/25 4:14:57 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ETHZ alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-38105
    Issuer: ETHZilla Corp
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 2875 South Ocean Blvd, Suite 200
    Palm Beach FLORIDA 33480
    Telephone number: (650) 507-0669
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Warrant
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2025-11-05 By Tara Petta AVP
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ETHZ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ETHZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ETHZ
    SEC Filings

    View All

    SEC Form S-8 filed by ETHZilla Corporation

    S-8 - ETHZilla Corp (0001690080) (Filer)

    11/6/25 5:12:31 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by ETHZilla Corporation

    25-NSE - ETHZilla Corp (0001690080) (Subject)

    11/5/25 4:14:57 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by ETHZilla Corporation

    DEF 14A - ETHZilla Corp (0001690080) (Filer)

    11/5/25 9:20:44 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ETHZilla Sells Approximately $40mm ETH to Facilitate Stock Repurchases

    Company has repurchased approximately 600k shares for about $12 million since Oct. 24, 2025 Company is buying back shares at a significant discount to NAV PALM BEACH, Fla., Oct. 27, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ)("ETHZilla" or the "Company"), a technology company connecting traditional finance and decentralized finance, today announced that it sold approximately $40 million of its ETH treasury holdings and plans to use the proceeds for share repurchases. Since executing the sale on Oct. 24, 2025, the Company has repurchased approximately 600,000 shares of its common stock for approximately $12 million under its existing board authorized $250 million stock repurchase

    10/27/25 4:00:00 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Announces Third Quarter 2025 Earnings Release Date and Webcast Details

    PALM BEACH, Fla., Oct. 24, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ), a leading technology company connecting traditional finance with decentralized finance, today announced it expects to release its financial results for the third quarter ended Sept. 30, 2025, before the U.S. markets open on Friday, Nov. 14, 2025. McAndrew Rudisill, chairman and chief executive officer, and John Saunders, vice president, finance, will host a live webcast on the same day at 10:30 a.m. EST, to discuss third quarter results and operational updates. To register and listen to the liv

    10/24/25 2:34:00 PM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Announces Strategic Partnership with Liquidity.io

    Accelerates ETHZilla's ability to securitize real-world assets on-chain  Offers exchange capabilities to expand investor access to compliant digital securities ETHZilla to take a 15% equity stake in Satschel, Inc. to further align interests PALM BEACH, Fla., Oct. 23, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), a technology company bridging traditional finance and decentralized finance, today announced a strategic partnership with Liquidity.io, a regulated broker-dealer and operator of a Digital Alternative Trading System (ATS), and a wholly owned subsidiary of Satschel, Inc. The partnership is expected to accelerate ETHZilla's institutional-grade to

    10/23/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ETHZ
    Leadership Updates

    Live Leadership Updates

    View All

    ETHZilla names John Kristoff as SVP, Corporate Communications and Investor Relations

    PALM BEACH, Fla., Oct. 16, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ), a leading technology company connecting traditional finance with decentralized finance, today announced the appointment of John D. Kristoff as Senior Vice President, Corporate Communications and Investor Relations. He will report directly to Chairman and CEO McAndrew Rudisill. In this newly created role, Kristoff will lead ETHZilla's communications and investor relations strategies, shaping the company's narrative and deepening engagement with both the media and investors. He will also play a k

    10/16/25 8:00:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ETHZilla Announces Appointment of Jason New to Board of Directors

    PALM BEACH, Fla., Oct. 8, 2025 /PRNewswire/ -- ETHZilla Corporation (NASDAQ:ETHZ) ("ETHZilla" or the "Company"), today announced that Jason New, Vice Chairman of Investment Banking at Lazard, has been appointed as a member of its Board of Directors, effective immediately. Mr. New brings more than two decades of experience in global credit, private equity, and alternative investments. He previously co-founded NovaWulf Management, a digital-asset investment and infrastructure platform, and served as Chief Executive Officer of Onex Credit Partners, a $25 billion alternative credi

    10/8/25 7:59:00 AM ET
    $ETHZ
    Biotechnology: Pharmaceutical Preparations
    Health Care